<DOC>
	<DOCNO>NCT00202722</DOCNO>
	<brief_summary>Remifentanil ultra short-acting synthetic opioid . It rapidly metabolize non-specific blood tissue esterases . We want investigate efficacy safety remifentanil use analgesia labour . Intravenous patient control analgesia ( ivpca ) use administer remifentanil . Doses use 0,15-1,05 mikrogr/kg , lock-out time 2 minute . 41 woman include study . Blood-pressure , heartrate , SaO2 , respiration rate sedation record every 15.minute . Fetal heart rate record whole periode treatment ( CTG , STAN ) . Vaginal contraction pain assess parturients every 15.minute use Visual Analogue Scale ( VAS ) . Midwives also record impression parturients pain . The parturients level sedation record anesthesiologist midwife every 15.minute . Apgar score register 1 , 5 10 min delivery . Umbilical cord blood analysis regard blood gas concentration remifentanil perform . After delivery , mother midwife evaluate efficacy safety ; Global satisfaction score , remifentanil dos sufficient , nausea , vomit , level sedation dizziness .</brief_summary>
	<brief_title>Remifentanil Intravenous Patient-controlled Analgesia ( IVPCA ) During Labour</brief_title>
	<detailed_description>Primary secondary outcome measure present `` result ''</detailed_description>
	<mesh_term>Labor Pain</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>Healthy woman ( ASA III ) , active labour , one fetus suspect pathology , expect normal childbirth , informed consent . Failure obtain informed consent , receive opioids within last 8 hour study start , serious sideeffects mother abnormal fetal heart rate .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Remifentanil , parenteral opioids , obstetric analgesia , IVPCA</keyword>
</DOC>